Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden.
Identifieur interne : 000A37 ( PubMed/Corpus ); précédent : 000A36; suivant : 000A38Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden.
Auteurs : Yu Kataoka ; Jordan Andrews ; Myngan Duong ; Tracy Nguyen ; Nisha Schwarz ; Jessica Fendler ; Rishi Puri ; Julie Butters ; Constance Keyserling ; John F. Paolini ; Jean-Louis Dasseux ; Stephen J. NichollsSource :
- Cardiovascular diagnosis and therapy [ 2223-3652 ] ; 2017.
Abstract
CER-001 is an engineered pre-beta high-density lipoprotein (HDL) mimetic, which rapidly mobilizes cholesterol. Infusion of CER-001 3 mg/kg exhibited a potentially favorable effect on plaque burden in the CHI-SQUARE (Can HDL Infusions Significantly Quicken Atherosclerosis Regression) study. Since baseline atheroma burden has been shown as a determinant for the efficacy of HDL infusions, the degree of baseline atheroma burden might influence the effect of CER-001.
DOI: 10.21037/cdt.2017.02.01
PubMed: 28567351
Links to Exploration step
pubmed:28567351Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden.</title><author><name sortKey="Kataoka, Yu" sort="Kataoka, Yu" uniqKey="Kataoka Y" first="Yu" last="Kataoka">Yu Kataoka</name><affiliation><nlm:affiliation>South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Andrews, Jordan" sort="Andrews, Jordan" uniqKey="Andrews J" first="Jordan" last="Andrews">Jordan Andrews</name><affiliation><nlm:affiliation>South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Duong, Myngan" sort="Duong, Myngan" uniqKey="Duong M" first="Myngan" last="Duong">Myngan Duong</name><affiliation><nlm:affiliation>South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Nguyen, Tracy" sort="Nguyen, Tracy" uniqKey="Nguyen T" first="Tracy" last="Nguyen">Tracy Nguyen</name><affiliation><nlm:affiliation>South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Schwarz, Nisha" sort="Schwarz, Nisha" uniqKey="Schwarz N" first="Nisha" last="Schwarz">Nisha Schwarz</name><affiliation><nlm:affiliation>South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Fendler, Jessica" sort="Fendler, Jessica" uniqKey="Fendler J" first="Jessica" last="Fendler">Jessica Fendler</name><affiliation><nlm:affiliation>South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Puri, Rishi" sort="Puri, Rishi" uniqKey="Puri R" first="Rishi" last="Puri">Rishi Puri</name><affiliation><nlm:affiliation>Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Butters, Julie" sort="Butters, Julie" uniqKey="Butters J" first="Julie" last="Butters">Julie Butters</name><affiliation><nlm:affiliation>South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Keyserling, Constance" sort="Keyserling, Constance" uniqKey="Keyserling C" first="Constance" last="Keyserling">Constance Keyserling</name><affiliation><nlm:affiliation>Cerenis Therapeutics SA, Labege, France.</nlm:affiliation></affiliation></author><author><name sortKey="Paolini, John F" sort="Paolini, John F" uniqKey="Paolini J" first="John F" last="Paolini">John F. Paolini</name><affiliation><nlm:affiliation>Cerenis Therapeutics SA, Labege, France.</nlm:affiliation></affiliation></author><author><name sortKey="Dasseux, Jean Louis" sort="Dasseux, Jean Louis" uniqKey="Dasseux J" first="Jean-Louis" last="Dasseux">Jean-Louis Dasseux</name><affiliation><nlm:affiliation>Cerenis Therapeutics SA, Labege, France.</nlm:affiliation></affiliation></author><author><name sortKey="Nicholls, Stephen J" sort="Nicholls, Stephen J" uniqKey="Nicholls S" first="Stephen J" last="Nicholls">Stephen J. Nicholls</name><affiliation><nlm:affiliation>South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28567351</idno><idno type="pmid">28567351</idno><idno type="doi">10.21037/cdt.2017.02.01</idno><idno type="wicri:Area/PubMed/Corpus">000A37</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A37</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden.</title><author><name sortKey="Kataoka, Yu" sort="Kataoka, Yu" uniqKey="Kataoka Y" first="Yu" last="Kataoka">Yu Kataoka</name><affiliation><nlm:affiliation>South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Andrews, Jordan" sort="Andrews, Jordan" uniqKey="Andrews J" first="Jordan" last="Andrews">Jordan Andrews</name><affiliation><nlm:affiliation>South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Duong, Myngan" sort="Duong, Myngan" uniqKey="Duong M" first="Myngan" last="Duong">Myngan Duong</name><affiliation><nlm:affiliation>South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Nguyen, Tracy" sort="Nguyen, Tracy" uniqKey="Nguyen T" first="Tracy" last="Nguyen">Tracy Nguyen</name><affiliation><nlm:affiliation>South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Schwarz, Nisha" sort="Schwarz, Nisha" uniqKey="Schwarz N" first="Nisha" last="Schwarz">Nisha Schwarz</name><affiliation><nlm:affiliation>South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Fendler, Jessica" sort="Fendler, Jessica" uniqKey="Fendler J" first="Jessica" last="Fendler">Jessica Fendler</name><affiliation><nlm:affiliation>South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Puri, Rishi" sort="Puri, Rishi" uniqKey="Puri R" first="Rishi" last="Puri">Rishi Puri</name><affiliation><nlm:affiliation>Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Butters, Julie" sort="Butters, Julie" uniqKey="Butters J" first="Julie" last="Butters">Julie Butters</name><affiliation><nlm:affiliation>South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Keyserling, Constance" sort="Keyserling, Constance" uniqKey="Keyserling C" first="Constance" last="Keyserling">Constance Keyserling</name><affiliation><nlm:affiliation>Cerenis Therapeutics SA, Labege, France.</nlm:affiliation></affiliation></author><author><name sortKey="Paolini, John F" sort="Paolini, John F" uniqKey="Paolini J" first="John F" last="Paolini">John F. Paolini</name><affiliation><nlm:affiliation>Cerenis Therapeutics SA, Labege, France.</nlm:affiliation></affiliation></author><author><name sortKey="Dasseux, Jean Louis" sort="Dasseux, Jean Louis" uniqKey="Dasseux J" first="Jean-Louis" last="Dasseux">Jean-Louis Dasseux</name><affiliation><nlm:affiliation>Cerenis Therapeutics SA, Labege, France.</nlm:affiliation></affiliation></author><author><name sortKey="Nicholls, Stephen J" sort="Nicholls, Stephen J" uniqKey="Nicholls S" first="Stephen J" last="Nicholls">Stephen J. Nicholls</name><affiliation><nlm:affiliation>South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Cardiovascular diagnosis and therapy</title><idno type="ISSN">2223-3652</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">CER-001 is an engineered pre-beta high-density lipoprotein (HDL) mimetic, which rapidly mobilizes cholesterol. Infusion of CER-001 3 mg/kg exhibited a potentially favorable effect on plaque burden in the CHI-SQUARE (Can HDL Infusions Significantly Quicken Atherosclerosis Regression) study. Since baseline atheroma burden has been shown as a determinant for the efficacy of HDL infusions, the degree of baseline atheroma burden might influence the effect of CER-001.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">28567351</PMID><DateCreated><Year>2017</Year><Month>06</Month><Day>01</Day></DateCreated><DateRevised><Year>2017</Year><Month>06</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2223-3652</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Cardiovascular diagnosis and therapy</Title><ISOAbbreviation>Cardiovasc Diagn Ther</ISOAbbreviation></Journal><ArticleTitle>Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden.</ArticleTitle><Pagination><MedlinePgn>252-263</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21037/cdt.2017.02.01</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">CER-001 is an engineered pre-beta high-density lipoprotein (HDL) mimetic, which rapidly mobilizes cholesterol. Infusion of CER-001 3 mg/kg exhibited a potentially favorable effect on plaque burden in the CHI-SQUARE (Can HDL Infusions Significantly Quicken Atherosclerosis Regression) study. Since baseline atheroma burden has been shown as a determinant for the efficacy of HDL infusions, the degree of baseline atheroma burden might influence the effect of CER-001.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">CHI-SQUARE compared the effect of 6 weekly infusions of CER-001 (3, 6 and 12 mg/kg) vs. placebo on coronary atherosclerosis in 369 patients with acute coronary syndrome (ACS) using serial intravascular ultrasound (IVUS). Baseline percent atheroma volume (B-PAV) cutoff associated with atheroma regression following CER-001 infusions was determined by receiver-operating characteristics curve analysis. 369 subjects were stratified according to the cutoff. The effect of CER-001 at different doses was compared to placebo in each group.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A B-PAV ≥30% was the optimal cutoff associated with PAV regression following CER-001 infusions. CER-001 induced PAV regression in patients with B-PAV ≥30% but not in those with B-PAV <30% (-0.45%±2.65% vs. +0.34%±1.69%, P=0.01). Compared to placebo, the greatest PAV regression was observed with CER-001 3mg/kg in patients with B-PAV ≥30% (-0.96%±0.34% vs. -0.25%±0.31%, P=0.01), whereas there were no differences between placebo (+0.09%±0.36%) versus CER-001 in patients with B-PAV <30% (3 mg/kg; +0.41%±0.32%, P=0.39; 6 mg/kg; +0.27%±0.36%, P=0.76; 12 mg/kg; +0.32%±0.37%, P=0.97).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Infusions of CER-001 3 mg/kg induced the greatest atheroma regression in ACS patients with higher B-PAV. These findings identify ACS patients with more extensive disease as most likely to benefit from HDL mimetic therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kataoka</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrews</LastName><ForeName>Jordan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duong</LastName><ForeName>MyNgan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Tracy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwarz</LastName><ForeName>Nisha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fendler</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puri</LastName><ForeName>Rishi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butters</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keyserling</LastName><ForeName>Constance</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cerenis Therapeutics SA, Labege, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paolini</LastName><ForeName>John F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Cerenis Therapeutics SA, Labege, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dasseux</LastName><ForeName>Jean-Louis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Cerenis Therapeutics SA, Labege, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicholls</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China (Republic : 1949- )</Country><MedlineTA>Cardiovasc Diagn Ther</MedlineTA><NlmUniqueID>101601613</NlmUniqueID><ISSNLinking>2223-3652</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2014 Nov;34(11):2465-72</RefSource><PMID Version="1">25212234</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2015 Sep 03;10(9):e0137584</RefSource><PMID Version="1">26335690</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Atherosclerosis. 2014 Jan;232(1):110-8</RefSource><PMID Version="1">24401224</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 2001 Apr;37(5):1478-92</RefSource><PMID Version="1">11300468</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circulation. 2012 Apr 17;125(15):1905-19</RefSource><PMID Version="1">22508840</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Ther. 2015 Dec 1;37(12):2716-31</RefSource><PMID Version="1">26548324</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2004 Mar 3;291(9):1071-80</RefSource><PMID Version="1">14996776</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2014 Dec 7;35(46):3277-86</RefSource><PMID Version="1">24780501</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 2010 Jun 15;55(24):2736-42</RefSource><PMID Version="1">20538166</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 2015 Mar;56(3):703-12</RefSource><PMID Version="1">25561459</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2013 Jun;34(24):1818-25</RefSource><PMID Version="1">23644179</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 2014 Aug 19;64(7):672-80</RefSource><PMID Version="1">25125298</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circ Res. 2006 Jun 9;98(11):1352-64</RefSource><PMID Version="1">16763172</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2012 Dec;32(12):2813-20</RefSource><PMID Version="1">23152494</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circ Res. 2004 Oct 15;95(8):764-72</RefSource><PMID Version="1">15486323</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Atherosclerosis. 2015 Oct;242(2):490-5</RefSource><PMID Version="1">26298740</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 2006 Mar 7;47(5):992-7</RefSource><PMID Version="1">16516083</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2013 Nov;34(41):3182-90</RefSource><PMID Version="1">23886915</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circ Res. 2012 Sep 28;111(8):1079-90</RefSource><PMID Version="1">23023510</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circ Res. 2014 Jan 3;114(1):171-82</RefSource><PMID Version="1">24385510</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2003 Nov 5;290(17 ):2292-300</RefSource><PMID Version="1">14600188</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2013 May 23;368(21):2004-13</RefSource><PMID Version="1">23697515</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 2008 Jul 22;52(4):255-62</RefSource><PMID Version="1">18634979</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Heart J Cardiovasc Imaging. 2014 Sep;15(9):1035-41</RefSource><PMID Version="1">24780871</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2015 Nov;35(11):2423-31</RefSource><PMID Version="1">26338299</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circulation. 2013 Sep 3;128(10):1112-21</RefSource><PMID Version="1">24002713</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">High-density lipoprotein (HDL)</Keyword><Keyword MajorTopicYN="N">acute coronary syndrome (ACS)</Keyword><Keyword MajorTopicYN="N">atheroma burden</Keyword><Keyword MajorTopicYN="N">intravascular ultrasound (IVUS)</Keyword><Keyword MajorTopicYN="N">regression</Keyword></KeywordList><CoiStatement>Conflicts of Interest: SJ Nicholls is a Principal Research Fellow of the National Health and Medical Research Council (NHMRC) of Australia and has received speaking honoraria from AstraZeneca, Amgen, Pfizer, Eli Lilly, Merck and Takeda, consulting fees from Amgen, AstraZeneca, Eli Lilly, Pfizer, Merck, Takeda, Roche, NovoNordisk, LipoScience and Anthera and research support from AstraZeneca, Cerenis, Amgen, Eli Lilly, Anthera, Sanofi-Regeneron, Novartis, Resverlogix and Lipid Sciences. R Puri is supported by the Neil Hamilton Fairley NHMRC Overseas Early Career Research Fellowship and has received consulting fees from Sanofi-Regeneron and Cerenis. Y Kataoka has received honoraria from Takeda, Kowa and Amgen Astellas BioPharma, and research support from Cerenis. Constance Keyserling, JF Paolini and JL Dasseux are employed by Cerenis Therapeutics. The other authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28567351</ArticleId><ArticleId IdType="doi">10.21037/cdt.2017.02.01</ArticleId><ArticleId IdType="pii">cdt-07-03-252</ArticleId><ArticleId IdType="pmc">PMC5440269</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A37 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000A37 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28567351
|texte= Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28567351" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |